1. Home
  2. MBBC vs BMEA Comparison

MBBC vs BMEA Comparison

Compare MBBC & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marathon Bancorp Inc.

MBBC

Marathon Bancorp Inc.

N/A

Current Price

$14.94

Market Cap

44.1M

Sector

Finance

ML Signal

N/A

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

N/A

Current Price

$0.58

Market Cap

42.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MBBC
BMEA
Founded
1902
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
44.1M
42.4M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
MBBC
BMEA
Price
$14.94
$0.58
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
★ $6.17
AVG Volume (30 Days)
1.4K
★ 1.5M
Earning Date
11-24-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 3200.00
69.19
EPS
★ 0.16
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$93.25
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.02
$0.54
52 Week High
$15.79
$2.24

Technical Indicators

Market Signals
Indicator
MBBC
BMEA
Relative Strength Index (RSI) 54.18 33.30
Support Level $14.58 $0.55
Resistance Level $15.39 $0.69
Average True Range (ATR) 0.16 0.06
MACD 0.05 0.03
Stochastic Oscillator 100.00 31.10

Price Performance

Historical Comparison
MBBC
BMEA

About MBBC Marathon Bancorp Inc.

Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: